Table 2:

Summary of abnormalities influencing in vivo efficacy of immunotherapeutic strategies

Factor	Summary	Reason
Trafficking	Insufficient immune effector cell trafficking or drug payload delivery to the site of tumor cells	inadequate chemokine stimulus morphological barrier
Recognition	Defective recognition of the targeted tumor antigen by cognate immune cells	abnormalities in antigen processing machinery abnormalities in recognition molecules
Survival	Low proliferation and limited persistence of effector immune cells in TME	deficiency in activatory cytokines and chemokines
Specificity	Side effects caused by the targeting of normal cells	expression of the targeted tumor antigen in normal tissues
Control	Side effects such as those caused by cytokine release syndrome	unregulated strength and timing of effector function
TME	Multiple escape mechanisms utilized by tumor cells	epigenetic changes in tumor cell phenotype and activity